Skip to content
Medical Health Aged Care

EarlyHealth Group Acquires CYB3R, Gulf’s Fastest-Growing Cybersecurity Firm

EarlyHealth Group 2 mins read

DUBAI, United Arab Emirates, Oct. 12, 2025 (GLOBE NEWSWIRE) -- EarlyHealth Group, a global pharmaceutical services and life sciences solutions company, has acquired a 50 % equity stake in CYB3R Limited, one of the Gulf’s fastest-growing cybersecurity firms headquartered in Dubai. This strategic diversification and cross-industry investment positions CYB3R with a global footprint whilst expanding its delivery of turnkey solutions to the life sciences industry and government organizations.

CYB3R, owned by tech entrepreneurs Alex Halsall and Jack Tupper, has rapidly gained prominence by securing critical infrastructure and sensitive data in regulated industries across the Middle East and Europe. By embedding CYB3R’s capabilities into EarlyHealth’s global platform, the partnership will scale operations internationally and deliver turnkey solutions that safeguard clinical studies, institutional programs, and government initiatives.

“With a growing portfolio of 1,200 international enterprises and public organizations, our partnership with EarlyHealth marks the next step in scaling CYB3R’s capabilities globally and delivering tailored cybersecurity solutions to our core sectors,” said Alex Halsall, Chief Executive Officer of CYB3R. “Together, we will establish a new benchmark for trusted, compliance-first digital security.”

CYB3R’s leadership team will remain in place post-acquisition, ensuring continuity in managing the current customer base while expanding its capabilities to serve new global markets.

EarlyHealth’s third acquisition this year underlines its drive to build a global conglomerate at the intersection of healthcare and digital transformation, delivering innovative solutions that expand access for patients, empower industry, and strengthen government capabilities worldwide.

20251010 EHG x CYB3R

About EarlyHealth Group
EarlyHealth Group is a global pharmaceutical services and life sciences company supporting manufacturing, clinical studies, and market access across 60 countries. The Group partners with biopharma, research institutions, and governments to make healthcare accessible through compliant, end-to-end solutions across the value chain.

About CYB3R
CYB3R is a Dubai-headquartered advanced cybersecurity company providing state-of-the-art SOC operations, managed detection and response (MDR), vulnerability testing, and compliance advisory. With a strong focus on applying AI to enhance security maturity, governance, risk and compliance (GRC), and data protection, CYB3R serves a diverse client base that includes government entities, healthcare providers, financial institutions, education networks, and international service providers.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/26f5855c-3e3a-4fa3-875b-be4bf1bc69ad


For media inquiries, please contact EarlyHealth Group Communications: [email protected]

Primary Logo

More from this category

  • Community, Medical Health Aged Care
  • 08/12/2025
  • 04:15
Save Our Sons Duchenne Foundation

Global Clinical Experts Gather in Sydney to Advance Adult Duchenne Muscular Dystrophy Care

Key Facts: Life expectancy for Australians living with DMD have increased from 18 for those borne before 1970, to around 30 today. As adult care remains fragmented and inconsistent between hospitals and States, the Symposium will develop global multi-disciplinary care recommendations.MEDIA RELEASE A world-first International Symposium dedicated toimproving multi-disciplinary clinical care for adults living with Duchenne muscular dystrophy (DMD) will take place in Sydney over the next three days. Hosted by the Save Our Sons Duchenne Foundation, the invitation-only event will bring together more than 35 of the world’s leading clinicians and researchers to develop the first multidisciplinary, global best-practice…

  • Contains:
  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.